Rheumatology Medical News about ankylosing spondylitis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Dramatic efficacy of infliximab in cauda equina syndrome complicating ankylosing spondylitis
Arthritis & Rheumatism, 06/04/09

Cornec D et al. - The authors managed the care of a 66-year-old man who had longstanding AS and clinical features of cauda equina syndrome, including anal incontinence and buttock hypoesthesia. Magnetic resonance imaging demonstrated no cause for these symptoms other than AS. The patient was treated with infliximab, a monoclonal antibody to tumor necrosis factor alpha that is used for the treatment of active AS. After 3 infliximab infusions, sphincter control and sensation were normal. The treatment was continued, and he was still doing well 1 year later.

<< Previous
The relationship between focal erosions and generalized...

Next >>
Association of a functional polymorphism in the IRF5 region with...